Day: December 23, 2024

Addition is part of the annual reconstitution of the Nasdaq Biotech Index (NBI) Inclusion criteria include minimum market capitalization and daily trading volumesAlvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its stock will be added to the Nasdaq Biotechnology Index (NASDAQ: NBI). The addition comes as a part of the annual reconstitution of the index. Alvotech’s inclusion in the NBI will be effective when the U.S. market opens on Monday, December 23, 2024. The Nasdaq Biotechnology Index contains securities of Nasdaq-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals. The Nasdaq Biotechnology Index is calculated under a modified capitalization-weighted...

Liven AS has harmonised the articles of associations of the group’s subsidiaries registered in Estonia and supplemented them, where necessary, with the right to establish a voluntary reserve. Among others, the amendment concerns the following subsidiaries that are considered significant subsidiaries according to the requirements of Nasdaq Tallinn: Liven Kodu OÜLiven Kodu 6 OÜLiven Kodu 12 OÜLiven Kodu 14 OÜLiven Kodu 15 OÜLiven Kodu 16 OÜLiven Kodu 18 OÜLiven Kodu 20 OÜ Translation of the item added to the articles of association (original in Estonian): One or more voluntary reserves (hereinafter referred to as the Voluntary Reserve) may be established by decision of the shareholders of the limited liability company (the Company), which shall be constituted either from annual allocations of net profits or from additional financial...

FALCON OIL & GAS LTD. (“Falcon”) Change of Auditors 23 December 2024 – Falcon Oil & Gas Ltd. (TSXV: FO, AIM: FOG) announces that BDO Canada LLP has been appointed as Falcon’s new auditor, replacing BDO LLP in the UK. Ends. CONTACT DETAILS:Falcon Oil & Gas Ltd.          +353 1 676 8702Philip O’Quigley, CEO +353 87 814 7042Anne Flynn, CFO +353 1 676 9162 Cavendish Capital Markets Limited (NOMAD & Broker)Neil McDonald / Adam Rae +44 131 220 9771About Falcon Oil & Gas Ltd. Falcon Oil & Gas Ltd is an international oil & gas company engaged in the exploration and development of unconventional oil and gas assets, with the current portfolio focused in Australia. Falcon Oil & Gas Ltd is incorporated in British Columbia, Canada and headquartered in Dublin, Ireland. For further...

(2024-12-23) Kitron has entered into a manufacturing contract with a leading technology company focusing on innovative IoT solutions. A five-year contract has been signed, and Kitron has received orders totalling EUR 15 million for delivery in 2025. The contract covers a gateway to sensors that transfer data to the cloud. The target application is assets tracking, monitoring shipments in the logistics sector. “We are extremely happy that the customer has chosen Kitron as a long-term production partner for its innovative IoT offering. Connectivity, including IoT, is one of Kitron’s prioritized market sectors, so this fits perfectly with our strategy,” said Mindaugas Sestokas, VP Central Eastern Europe. Production will take place at Kitron’s facility in Kaunas, Lithuania, and the scope is high-level assembly. For further...

Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 23 Dec 2024 – 7AM CET Fagron updates on FDA communication regarding the June 2024 inspection at Wichita Following the FDA’s routine inspection at Fagron’s Wichita facility conducted in June 2024, the Company received a warning letter from the FDA (Warning Letter) on December 19, 2024. The Warning Letter requires Fagron to enhance processes for investigating discrepancies, and validations of future manufacturing capacity. The majority of these improvements have already been addressed, and Fagron is collaborating with the FDA to clarify any outstanding items and achieve a satisfactory resolution. After the June inspection, the Company responded to the FDA on July 19, August 30, September 27, October 25, and November 22, 2024 addressing the Agency’s...

Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccinesPneumococcal disease remains a major global health challenge despite the availability of current vaccines This 21-valent pneumococcal conjugate vaccine (PCV21) is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter phase 3 in infants & toddlersParis, December 23, 2024. Sanofi and SK bioscience have entered into a new chapter of their collaboration in pneumococcal vaccines with an expanded agreement to develop, license and commercialize next-generation PCVs for both pediatric and adult populations, reaffirming their commitment to fighting pneumococcal disease. Despite decades of public health vaccination programs, invasive pneumococcal disease (IPD) continues...

Additional funding awarded following successful drug candidate nomination USD 7.3 million to support progression of antibiotic BAL2420 (LptA inhibitor) towards first-in-human clinical studiesAd hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 23, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it was awarded an additional USD 7.3 million from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to supporting the early development of antibacterial products. The new funding supports the progression of Basilea’s novel antibiotic candidate BAL2420 (LptA inhibitor) towards the start of first-in-human...

Interim information of Grigeo Group AB will be prepared and financial results will be released on these dates:February 25, 2025 – Interim Financial Statements for 12 months of 2024. April 8, 2025 – Annual audited Financial Statements for the year 2024. May 23, 2025 – Interim Financial Statements for 3 months of 2025. August 22, 2025 – Interim Financial Statements for 6 months of 2025. November 21, 2025 – Interim Financial Statements for 9 months of 2025.On April 30, 2025, the Company plans to hold an ordinary general meeting of shareholders. Tomas Jozonis Chief Executive Officer +370 5 243 58 01